STAGE III BREAST CANCER AJCC V7

This phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…

This early-phase trial is testing whether a gel form of the drug endoxifen can be safely applied to the skin in women scheduled for breast surgery. The study includes 32 women with various stages of breast cancer or high genetic risk. Researchers are checking for skin reactions a…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…

This study tests whether a newer drug, Z-Endoxifen, works better than the standard tamoxifen for postmenopausal women with advanced ER+/HER2- breast cancer. About 81 participants will receive one of the two hormone therapies to see which delays cancer growth longer. The goal is t…

This study tests whether adding the immunotherapy drug pembrolizumab after standard chemotherapy helps prevent breast cancer from returning in people with triple-negative breast cancer. About 1,155 participants who still had cancer after chemo will receive either pembrolizumab or…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy before surgery helps shrink tumors more than chemo alone in people with stage II-III triple negative breast cancer. About 67 participants will receive either chemo alone or chemo plus ate…

This phase 2 trial tests whether electroacupuncture can reduce chronic pain in women who have completed treatment for stage I-III breast cancer. 111 participants will receive either real acupuncture, sham acupuncture, or no treatment. The goal is to see if this gentle needle ther…

This study looks at whether an integrative oncology program—including diet advice, physical activity, stress management, social support, and reducing exposure to environmental toxins—can improve outcomes for women with stage II or III breast cancer who are receiving radiation the…